Iradimed Co (IRMD)vsMerck & Company Inc (MRK)
IRMD
Iradimed Co
$83.44
-0.32%
HEALTHCARE · Cap: $1.07B
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 77466% more annual revenue ($65.01B vs $83.81M). MRK leads profitability with a 28.1% profit margin vs 26.8%. MRK appears more attractively valued with a PEG of 3.36. IRMD earns a higher WallStSmart Score of 60/100 (C).
IRMD
Buy60
out of 100
Grade: C
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-81.7%
Fair Value
$56.73
Current Price
$83.44
$26.71 premium
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.3%
Every $100 of equity generates 25 in profit
Keeps 27 of every $100 in revenue as profit
17.0% revenue growth
Earnings expanding 24.8% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Trading at 11.3x book value
Smaller company, higher risk/reward
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : IRMD
The strongest argument for IRMD centers on Operating Margin, Return on Equity, Profit Margin. Profitability is solid with margins at 26.8% and operating margin at 31.3%. Revenue growth of 17.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : IRMD
The primary concerns for IRMD are Price/Book, Market Cap, PEG Ratio. A P/E of 47.8x leaves little room for execution misses.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
IRMD profiles as a growth stock while MRK is a value play — different risk/reward profiles.
IRMD carries more volatility with a beta of 1.12 — expect wider price swings.
IRMD is growing revenue faster at 17.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
IRMD scores higher overall (60/100 vs 59/100), backed by strong 26.8% margins and 17.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Iradimed Co
HEALTHCARE · MEDICAL DEVICES · USA
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?